Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for TG Therapeutics, Inc. (TGTX : NSDQ)

• Company Description    TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York. Number of Employees: 286

• Price / Volume Information    Yesterday's Closing Price: $5.39 Daily Weekly Monthly 20 Day Moving Average: 2,555,479 shares Shares Outstanding: 144.43 (millions) Market Capitalization: $778.50 (millions) Beta: 2.25 52 Week High: $41.00 52 Week Low: $4.81 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -27.36% -18.19% 12 Week -45.22% -39.79% Year To Date -71.63% -61.16%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 2 GANSEVOORT STREET 9TH FLOOR - NEW YORK,NY 10014 USA ph: 212-554-4484 fax: 212-554-4531 ir@tgtxinc.com http://www.tgtherapeutics.com

• General Corporate Information    Officers Michael S. Weiss - Chairman and Chief Executive Officer Sean A. Power - Chief Financial Officer Laurence N. Charney - Director Yann Echelard - Director Kenneth Hoberman - Director Peer Information TG Therapeutics, Inc. (BJCT) TG Therapeutics, Inc. (CADMQ) TG Therapeutics, Inc. (APNO) TG Therapeutics, Inc. (UPDC) TG Therapeutics, Inc. (IMTIQ) TG Therapeutics, Inc. (CYGN) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED PRODUCTS Sector: Medical CUSIP: 88322Q108 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/01/22 Share - Related Items Shares Outstanding: 144.43 Most Recent Split Date: 4.00 (0.02:1) Beta: 2.25 Market Capitalization: $778.50 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.44 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.02 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/01/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 4.57 Price/Cash Flow: - Price / Sales: 98.40 EPS Growth vs. Year Ago Period: 26.09% vs. Previous Quarter: 27.14% Sales Growth vs. Year Ago Period: 154.22% vs. Previous Quarter: -13.14% ROE 03/31/22 - -118.49 12/31/21 - -101.11 09/30/21 - -82.68 ROA 03/31/22 - -82.98 12/31/21 - -76.53 09/30/21 - -66.42 Current Ratio 03/31/22 - 4.43 12/31/21 - 5.06 09/30/21 - 4.24 Quick Ratio 03/31/22 - 4.43 12/31/21 - 5.06 09/30/21 - 4.24 Operating Margin 03/31/22 - -4,126.45 12/31/21 - -5,204.07 09/30/21 - -7,784.36 Net Margin 03/31/22 - -4,126.45 12/31/21 - -5,204.07 09/30/21 - -7,784.36 Pre-Tax Margin 03/31/22 - -4,126.47 12/31/21 - -5,204.08 09/30/21 - -7,784.36 Book Value 03/31/22 - 1.18 12/31/21 - 1.68 09/30/21 - 2.20 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - 0.39 12/31/21 - 0.28 09/30/21 - 0.00 Debt-to-Capital 03/31/22 - 28.30 12/31/21 - 21.97 09/30/21 - 0.00

Powered by Zacks Investment Research ©